# A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

> **NCT02826161** · PHASE3 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Napabucasin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02826161
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2017-04-24
- **Final completion:** 2017-04-24
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Change of treatment landscape and evolving standard of care
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826161, "A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02826161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*